Sanara MedTech Inc.
SMTIHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Sanara MedTech Inc. focuses on Medical Instruments & Supplies services and products. Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. At a $233.7M market cap, Sanara MedTech Inc. ranks as a micro-cap company within healthcare. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns.
Market Cap
$233.7M
Beta
1.18
P/E (TTM)
425.00
P/E (Fwd)
47.22
EPS (TTM)
$0.06
EPS (Fwd)
$0.54
ROE
2.9%
ROA
8.3%
Cash
$13.6M
Total Debt
$48.4M
Free CF
$5.8M
52W Change
-3.3%
Annual Financials
Cash vs Debt
Where SMTI stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, SMTI finished 10.25% above its 150-day moving average ($21.27) and 3.40% above its 200-day moving average ($22.68). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SMTI overbought or oversold?
At the July 15, 2026 close, SMTI's RSI(14) was 59.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $13.6M in cash, though total debt stands at $48.4M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $5.8M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 2.9% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $45.8M (2022) to $103.1M (2025), reflecting a 125% increase over the period.
At over 50x earnings, SMTI carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SMTI.